Validity of the GUSTO trial's main conclusion

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 850-852

  Eisenberg, Charles ^a  

^a Salina Regional Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; INOTROPISM; NOTE; TREATMENT OUTCOME;

CLINICAL TRIALS; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030854984     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (8)

1. Stringer KA. Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996;16(5 pt 2):119S-26.
2. Talbert RL. Strategies in the management of acute myocardial infarction. Pharmacotherapy 1996;16(5 pt 2):127S-36.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N EnglJ Med 1993;329:673-82.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
5. Sleight P. Streptokinase is still the agent of choice for most patients with myocardial infarction. Am J Ther 1995;2:128-35.
6. Rapaport E. GUSTO: assessment of the preliminary results. J Myocard Ischem 1993;5(8):15-24.
7. Albrich MJ. Acute myocardial infarction: comprehensive guidelines for diagnosis, stabilization, and mortality reduction. Emerg Med Rep 1994;15(6):51-61.
8. Ridker PM, O'Donnell CJ, Marder VJ, Hennekens CH. A response to "Holding GUSTO up to the light." Ann Intern Med 1994;120(10)882-5.